23 August 2021>: Clinical Research
Cost-Benefit Analysis of Using A Single Dose of Tranexamic Acid in Degenerative Lumbar Scoliosis Patients Undergoing Long-Segment Spinal Fusion Surgery: A Retrospective Study
Lei Yuan 123BCE* , Yu Jiang 123BD* , Yinhao Liu 123BF , Yan Zeng 123ADF* , Zhongqiang Chen 123A , Weishi Li 123BDOI: 10.12659/MSM.930352
Med Sci Monit 2021; 27:e930352
Table 4 Data from subanalyses of TXA pricing and units of transfused PRBCs for non-osteotomy and osteotomy constructs with or without intraoperative TXA.
Non-osteotomy (n=72) | Osteotomy (n=101) | |||||
---|---|---|---|---|---|---|
NTXA (n=59) | TXA (n=13) | P value | NTXA (n=60) | TXA (n=41) | P value | |
Transfusion-treated patients | 53(89.9%) | 10(76.9%) | 0.418 | 58(96.7%) | 37(90.2%) | 0.362 |
PRBC units given during hospital stay | 4.08± 3.27 | 2.77± 2.39 | 0.175 | 5.72± 3.35 | 3.73± 2.30 | ** |
TXA cost per patient | ¥0 | ¥9.60 | – | ¥0 | ¥9.60 | – |
PRBC unit acquisition-only cost | ¥898.64± 719.63 | ¥609.23± 524.89 | 0.175 | ¥1257.67± 735.92 | ¥820.98± 506.54 | ** |
PRBC unit net acquisition-only cost+TXA cost | ¥898.64± 719.63 | ¥618.83± 524.89 | 0.190 | ¥1257.67± 735.92 | ¥830.58± 506.54 | ** |
PRBC unit total cost | ¥922.37± 738.70 | ¥622.69± 539.55 | 0.172 | ¥1496.42± 1027.92 | ¥838.05± 516.46 | ** |
PRBC unit net total cost+ TXA cost | ¥922.37± 738.70 | ¥632.29± 539.55 | 0.186 | ¥1496.42± 1027.92 | ¥847.65± 516.46 | ** |
TXA, the group that received tranexamic acid; NTXA – the historically recruited no-TXA group; PRBC – packed red blood cells; ** |